ClinicalTrials.gg
CompletedNCT07153146Updated Aug 5, 2026

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PN-881 in Healthy Subjects.

A Phase 1 interventional study of PN-881 Oral Solution and PN-881 Oral Tablet in Healthy Volunteer, sponsored by Protagonist Therapeutics, Inc.. Completed at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Protagonist Therapeutics, Inc. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
146
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PN-881 in healthy adult participants.

Read the detailed description

PN-881 will be administered in oral solution and tablet formulations, with dosing under fasting or fed conditions depending on the study part.

The study consists of five parts:

Part 1 - Single Ascending Dose (SAD): Randomised, double-blind, placebo-controlled Part 2 - Multiple Ascending Dose (MAD): Randomised, double-blind, placebo-controlled Part 3 - Tablet Formulation Comparison: Open-label, crossover design; participants will receive different oral tablet formulations Part 4 - Effect of Food: Open-label, crossover design to assess the effect of food on the pharmacokinetics of PN-881. Participants will receive PN-881 tablet formulations in fasted and fed conditions.

Part 5 - Dosing Frequency Comparison: Open-label, randomized study comparing once-daily and twice-daily dosing.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • PN-881
03

In context

Lead sponsor

Protagonist Therapeutics, Inc. is the lead sponsor of 13 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 1 (11%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female participants of non-, aged 18-65 years inclusive
  2. (BMI) between 18 and 32 kg/m² (inclusive) at screening
  3. Willing and able to comply with all study requirements and provide written
  4. Male participants with female partners of childbearing potential must agree to use highly effective during the study and for 90 days after the last dose

Exclusion criteria

Exclusion Criteria:

  1. history or presence of cardiovascular, gastrointestinal, hepatic, renal, neurological, psychiatric, or allergic diseases
  2. History of neoplastic disease (except adequately treated non-melanoma skin cancer)
  3. Positive test for , , or at screening
  4. History of substance abuse or recreational IV drug use within the past 2 years
  5. Clinically significant infection or fever (>38°C) within 2 weeks prior to screening
  6. Use of any prescription/non-prescription drugs or herbal supplements within 7 days or 5 half-lives before dosing (unless approved by investigator)
  7. Supine blood pressure or abnormalities outside protocol-defined ranges
  8. Use of tobacco/nicotine products exceeding 5 cigarettes/day or 2 chews/day
  9. Consumption of >21 alcohol units/week (males) or >14 units/week (females)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
146 participants (actual)

Study arms

  • Experimental
    PN-881 Oral Solution Single Ascending Dose

    PN-881 Oral Solution Single Ascending Dose

    Drug: PN-881 Oral Solution

  • Placebo comparator
    Placebo Oral Solution Single Ascending Dose

    Placebo single ascending doses

    Drug: Placebo

  • Experimental
    PN-881 Oral Solution Multiple Ascending Dose

    PN-881 Multiple Ascending Doses

    Drug: PN-881 Oral Solution

  • Placebo comparator
    Placebo Oral Solution Multiple Ascending Dose

    Placebo, multiple ascending doses

    Drug: Placebo

  • Experimental
    PN-881 Oral Tablet Single Dose

    PN-881 oral tablet single dose

    Drug: PN-881 Oral Tablet

  • Experimental
    PN-881 Oral Tablet Multiple Dose

    PN-881 oral tablet multiple dose

    Drug: PN-881 Oral Tablet

Interventions

  • DrugPN-881 Oral Solution

    PN-881 Oral Solution

  • DrugPN-881 Oral Tablet

    PN-881 oral tablet

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Incidence and severity of treatment-emergent adverse events (TEAEs)

    Evaluate the safety and tolerability of PN-881 in comparison to placebo after single and multiple doses in healthy subjects assessed for severity, seriousness, and relation to the investigational product.

    Time frame: Predose to 7 days after last dose

Secondary outcomes

  1. Maximum observed plasma concentration (Cmax) of PN-881

    Highest measured plasma concentration of PN-881 following oral administration.

    Time frame: 48 hours following the first dose and the last dose

  2. Area under the plasma concentration-time curve (AUC) of PN-881

    AUC calculated from 0 to infinity.

    Time frame: Predose to 48 hours after the first and last dose.

  3. Levels of biomarker in serum

    Pharmacodynamics (PD) of PN-881 by means of increase in levels of biomarker by PN-881 after single and multiple oral doses.

    Time frame: Day 1 Predose up to 48 hours post (last) dose

07

Study locations

1 site
  • Nucleus Network
    Melbourne, Victoria 3004, Australia
08

References and documents

Individual participant data

Plan to share: No — Phase I study

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2025 to primary completion in Jul 2026, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2025
First posted
Sep 3, 2025
StartActual
Oct 7, 2025
Primary completionActual
Jul 29, 2026
CompletionActual
Jul 29, 2026
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07153146
Lead sponsor
Protagonist Therapeutics, Inc.
Responsible party
Sponsor
First posted
Sep 3, 2025
Start date
Oct 7, 2025
Primary completion
Jul 29, 2026
Completion
Jul 29, 2026
Last update
Aug 5, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion